Immuron Ltd (IMRN) Form 6-K — Jul 20, 2026
Immuron reported FY26 global sales revenue of A$7.7 million, a 6% increase year-over-year, driven by strong performance in Australia and the U.S. The company's cash position improved to A$10.0 million as of December 31, 2025, providing approximately 22.5 months of runway based on first-half operating cash usage. Management highlighted a strategic reset to partner clinical assets IMM-124E and IMM-529, aiming to reduce R&D expenses and accelerate monetization through licensing deals. The IND application for IMM-529 was approved by the FDA in November 2025, clearing the way for Phase 2 clinical trials for C.
Key figures
- Revenue
- A$7.7 million
- Revenue Yoy
- 6%
- Cash Position
- A$10.0 million
- Us Sales
- A$1.8 million
- Market Cap
- A$13.882 million
- Cash Runway
- 22.5 months
- Canada Sales
- A$0.2 million
- Ebitdx ex rd
- -A$1.1 million
- Australia Sales
- A$5.8 million
- Shares Outstanding
- 322,848,081
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.